China’s Hansoh Teams Up with Middle East Onco-Collaborator

Tabuk Pharmaceutical Manufacturing Company, headquartered in Riyadh, and Hansoh Pharmaceutical Ltd. a leading Chinese pharmaceutical company based in Jiangsu, have announced an agreement to commercialize several oncology & specialty products in Saudi Arabia and other Middle East markets.

Tabuk and Hansoh Pharma – the Collaborators

Established in 1994, Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group) is the largest privately-owned pharmaceutical company in Saudi Arabia, with a strong market presence across 17 countries throughout the Middle East and North Africa (MENA) region. 

Hansoh Pharma, on the other hand, is a leading innovation-driven pharmaceutical company ranked in the top 30 among China’s Top 100 Companies in Pharmaceutical Industry. With a corporate mission to “create excellence in pharmaceuticals, enhance innovation in China”, Hansom pharma after more than 20 years of continuous investment in R&D, has so far five Class 1 innovative drugs in the market, more than 100 drugs in development, and more than 20 innovative drugs in the clinical stage, forming a rich pipeline. 

The Agreement and its Implications

Under the terms of the agreement, Tabuk Pharmaceuticals will have exclusive rights to hold the marketing authorization for oncology & specialty products and will be responsible to register, import, and promote medications in Saudi Arabia and Middle East countries.

Wisam Alkhatib, Vice President of Strategy and Business Development of Tabuk Pharmaceuticals said: “Tabuk is delighted to partner with one of the largest pharmaceutical entities in China, to further expand and ensure the availability of essential and lifesaving products for patients in the region. 

“We believe Hansoh’s extensive experience in clinical and product development in these therapeutic classes make them an ideal partner to cooperate with and support Tabuk’s growth aspirations,” he added.

“As part of our role and mission in Tabuk to deliver unique health solutions and preserve lives for the people of Saudi Arabia and countries, we operate in especially during the current pandemic, our partnership with Hansoh comes in as an evident choice to further support our mission in line with Saudi vision 2030 regarding localisation of oncology & specialty medicine”, said Mohammed Al Hagbani, President of Astra Industrial Group.

Hansoh Pharma on its part sees this as an important step in achieving its ambitions of globalisation.

“This agreement widens the sales territories of Hansoh’s products in the Middle East and North Africa market”, said Suzuki Wong, General manager of the International Business Division of Hansoh. “Besides, this agreement also brings the opportunity to receive treatment with oncology and specialty drugs to the local patients. We believe that the collaboration between Hansoh and Tabuk will enable the launch of products in the territories for the first time, and the two parties will complement each other’s strengths and fulfil the established sales expectations.”

Author

Arvind C. Shekhar